Abviris

Executive Summary

Abviris is a German diagnostics pioneer specializing in HPV serology, with its lead product Prevo-Check® enabling early detection and post-treatment monitoring of HPV-induced tumors from a single drop of blood. Founded in 2018 and headquartered in Berlin, the company addresses a critical gap in cervical cancer screening by offering a non-invasive blood test that can identify precancerous lesions earlier than traditional methods. This approach has the potential to improve patient outcomes and quality of life while reducing healthcare costs. Although the company is still in its early stages and has not disclosed funding or valuation, its innovative technology positions it well in the growing liquid biopsy market. With HPV being a leading cause of several cancers, Abviris's platform could expand beyond cervical cancer to other HPV-related malignancies, offering significant commercial and clinical upside. The company remains privately held and has yet to announce major partnerships or regulatory milestones, but its technology has attracted interest from the oncology diagnostics space.

Upcoming Catalysts (preview)

• Q3 2026CE Marking Approval for Prevo-Check in Europe70% success
• Q4 2026Strategic Partnership with a Major Diagnostic Laboratory Network50% success
• Q2 2026Publication of Clinical Validation Study Results in a Peer-Reviewed Journal80% success